|
Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, IHS, OS, OSG, SAMHSA
|
NIDA, NIAAA
|
The Consolidated Appropriations Act of 2004 directed the Secretary of Health and Human Services (HHS) to establish the Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) and to issue an annual report summarizing all Federal agency activities related to preventing underage alcohol use. HHS made ICCPUD a standing committee to provide ongoing, high-level leadership on this issue and to serve as a mechanism for coordinating Federal efforts aimed at preventing and reducing underage drinking. The Substance Abuse and Mental Health Services Administration (SAMHSA) serves as the lead ICCPUD agency.
|
|
Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM)
|
Research Initiative
|
ATSDR, CDC, FDA
|
NIEHS, NCI, NEI, NIAID, NLM
|
The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) is an interagency committee of 15 Federal agencies that carries out specific duties prescribed by the ICCVAM Authorization Act, P.L. 106-545. The ICCVAM is administered by the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), a component of the NIEHS. NICEATM in collaboration with ICCVAM and its international collaborators in Japan, the EU, and Canada conducts research studies to evaluate the scientific validity of proposed new safety testing methods. NICEATM and ICCVAM also conduct international scientific peer review evaluations of proposed safety methods, and forward recommendations on scientific valid methods to Federal agencies, which must adopt the proposed methods or provide a basis for not adopting it. NICEATM and ICCVAM also organize scientific workshops to evaluate the current state of the science on a wide range of toxicological and other safety endpoints.
|
|
Interagency Dual Use Outreach Working Group (IDOWG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NIAID
|
This working group develops strategies to educate the research community about Dual Use Research of Concern (DURC) and the DURC-related USG policies
|
|
Interagency Epilepsy Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, CMS, FDA, HRSA
|
NICHD, NIA, NIMH, NINDS
|
This group seeks to improve research about epilepsy.
|
|
Interagency Group on Alzheimer''s Disease and Related Dementias for implementation of the National Alzheimer''s Project Act
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA
|
NIA
|
This interagency group was established by HHS in response to the Congressional directive to address Alzheimer disease. Under the National Alzheimer’s Project Act, HHS created three sub-groups on Research, Long Term Services, and Clinical Services. The Veteran’s Administration, National Science Foundation, and Department of Defense are also involved in this effort.
|
|
Interagency Midazolam Product Coordination Team
|
Committee, Work group, Advisory group, or Task Force
|
FDA, OS
|
NINDS
|
A collaboration led by the Department of Health and Human Services (HHS) to facilitate activities, both research and regulatory, related to the Food and Drug Administration (FDA) approval of midazolam for use in treating nerve agent exposure.
|
|
Interagency Modeling and Analysis Group (IMAG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIBIB, CSR, NCI, NHGRI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NLM, OD/DPCPSI/OBSSR
|
The Inter-agency Modeling and Analysis Group (IMAG) is comprised of program directors from nine government agencies in the U.S. including the National Institutes of Health (NIH), the National Science Foundation (NSF), Department of Energy (DOE), Department of Defense (DOD), the Department of Agriculture (USDA), the National Aeronautics and Space Administration (NASA), the Department of Veterans Administration (VA), the Food and Drug Administration (FDA), and the Intelligence Advanced Research Projects Activity (IARPA). The purpose of IMAG is to bring together program officers who have a shared interest in supporting modeling and analysis methods in biomedical, biological and behavioral systems. IMAG has promoted and supported a wide variety of modeling, notably the multi-scale modeling (MSM) initiative, which was originally a multi-agency funding opportunity announcement and continued on by various IMAG agencies through other funding opportunity announcements. The most recent multi-agency funding opportunity was issued in 2015 and expires in 2018. IMAG is planning a tenth anniversary consortium meeting in March 2017.
|
|
Interagency Pain Research Coordinating Committee (IPRCC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA
|
NINDS, NCCIH, NIDA, NIDCR, NINR
|
The Interagency Pain Research Coordination Committee is an Affordable Care Act mandated committee to coordinate pain research activities across the government.
|
|
Interagency Precision Medicine Initiative Working Group (IPMI WG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA, OS
|
OD/OSP
|
The IPMI WG coordinates activities across the Federal government to enhance innovation in precision medicine, with the ultimate goal of moving the United States into an era where medical care can be more precisely tailored to each patient and the best outcomes can be achieved for all.
|
|
Interagency Select Agent Review Group (ISARG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NIAID, OD/OM/OB, OD/OSP
|
The Interagency Select Agent Review Group (ISARG), composed of members from the Centers for Disease Control and Prevention (CDC), the Department of Justice, the Department of State, the NIH-OD and BARDA, advises the National Institute of Allergy and Infectious Diseases (NIAID) on whether facilities and procedures at NIAID-funded foreign research sites are comparable to those required by the Select Agent Regulations for domestic institutions before Select Agent work at the foreign site may proceed.
|